eigentlich poste ich ja nicht unbedingt personalien,
aber wenn ichs richtig lese gehts auch langsam um die vermarktung von Pro140
(man möge mich gerne berichtigen)
CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman
www.bloomberg.com/press-releases/...olo-as-executive-chairman
Auszug:
CytoDyn Inc.
(OTC.QB:CYDY), a biotechnology company focused on the development of new
antibody therapies for combating human immunodeficiency virus (HIV) infection,
announces the appointment of Anthony D. Caracciolo as Executive Chairman of
CytoDyn effective immediately. In this new capacity, Mr. Caracciolo will
assume an active leadership role in the Companys strategic planning, business
development and operations. Nader Pourhassan, Ph.D., will continue to serve
as President and Chief Executive Officer, and Mr. Caracciolo will retain his
position as Chairman of the Board.
We are committed to increasing shareholder value and this appointment is
aimed at strengthening our management team and driving our corporate
strategy, said Dr. Pourhassan. Mr. Caracciolos significant industry and
operational experience is expected to be highly valuable in directing our
ongoing clinical trials and enhancing business development efforts as we
pursue broader strategic opportunities for our late-stage PRO 140 technology
to increase the franchise value of our pipeline.